Vivos Therapeutics Inc. (VVOS) Prices 3.5M Share IPO at $6/Sh

Vivos Therapeutics Inc. (NASDAQ: VVOS), a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, today announced the pricing of its initial public offering of 3,500,000 shares of its common stock at a public offering price of $6.00 per share. The shares of common stock are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “VVOS” on Friday, December 11, 2020.

The aggregate gross proceeds to Vivos from the public offering are expected to be $21 million prior to deducting underwriting discounts, commissions and other estimated offering expenses. Vivos has granted the underwriters a 45-day option to purchase up to an additional 525,000 shares of common stock to cover over-allotments, if any.

Roth Capital Partners is acting as lead book-running manager and representative of the underwriters for the offering. Craig-Hallum Capital Group and National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (NHLD) are acting as co-managers of the offering.

The Securities and Exchange Commission declared effective a registration statement on Form S-1 relating to these securities on December 10, 2020.

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• Singularity Future Technology closes $1.8M registered direct offering
• Nscale targets up to $3B in US IPO as soon as September - Bloomberg